biotech · Propionic Acidemia · Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
SOM Biotech
Moderna Biotech Spain
Moderna Biotech Spain is a biotech organization headquartered in EU. Primary therapeutic focus areas include Propionic Acidemia, Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency, Glycogen storag
Barcelona, ES HQ
2009 Founded
14 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Barcelona, ES
- Founded
- 2009
- Employees
- 14
- Programs
- 10
- Drugs
- 27
- Patents
- 0
mRNA-3927-P101
Phase 2 · small molecule · Propionic Acidemia
mRNA-3927-P101 for Propionic Acidemia is a Phase 2 program (small_molecule) at Moderna Biotech Spain with 1 ClinicalTrials.gov record(s).
Internal code mRNA-3927-P101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Moderna Biotech Spain
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Propionic Acidemia
- Status
- active
- Trials
- 1